Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: Evidence from Y2 receptor knockout mice

Behavioural Brain Research

Volumn 141, Issue 2, 2003, Pages 251-255

  Redrobe, John P ^a   Dumont, Yvan ^a   Herzog, Herbert ^b   Quirion, Rémi ^a  

^a MCGILL UNIVERSITY   (Canada)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Anxiety; Elevated plus maze; Mice; Neuropeptide Y; Open field; Y2 receptors

Indexed keywords

NEUROPEPTIDE Y2 RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; MALE; MAZE LEARNING; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PHENOTYPE; RECEPTORS, NEUROPEPTIDE Y;

EID: 0038756033     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(02)00374-1     Document Type: Article

References (49)

1. 2 receptors regulate bone formation. J. Clin. Invest. 109:2002;915-921.
2. Bannon A.W., Seda J., Carmouche M., Francis J.M., Norman M.H., Karbon B.et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 868:2000;79-87.
3. Belzung C., Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav. Brain Res. 125:2001;141-149.
4. Benoit-Marand M., Borrelli E., Gonon F. Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J. Neurosci. 21:2001;9134-9141.
5. Bourin M., Hascoet M. Drug mechanisms in anxiety. Curr. Opin. Investig. Drugs. 2:2001;259-265.
6. Colmers W.F., Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci. 17:1994;373-379.
7. Cruz A.P.M., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49:1994;171-176.
8. 2 receptor antagonist. Eur. J. Pharmacol. 384:1999;R3-R5.
9. Dumont Y., Cadieux A., Doods H.N., Pheng L.H., Abounader R., Hamel E.et al. BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br. J. Pharmacol. 129:2000;1075-1088.
10. Dumont Y, Jacques D, St-Pierre JA, Tong Y, Parker R, Herzog H, et al. Neuropeptide Y, peptide YY and pancreatic polypeptide receptor proteins and mRNAs in mammalian brain. In: Quirion R, Bjorklund A, Hokfelt T, editors. Handbook of chemical neuroanatomy, vol. 16. London: Elsevier; 2000. p. 375-475.
11. File SE. Behavioural detection of anxiolytic action. In: Elliot JM, Heal DJ, Marsden CA, editors. Experimental approaches to anxiety and depression. Chichester: John Wiley & Sons Ltd; 1992. p. 25-44.
12. Flood J.F., Hernandez E.N., Morley J.E. Modulation of memory processing by neuropeptide Y. Brain Res. 421:1987;280-290.
13. Gray J.A., Lalljee B. Sex differences in emotional behaviour in the rat: correlation between open-field defecation and active avoidance. Anim. Behav. 22:1974;856-861.
14. Gregor P., Feng Y., DeCarr L.B., Cornfield L.J., McCaleb M.L. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J. Biol. Chem. 271:1996;27776-27781.
15. Handley S.L., Mithani S. Effects of alpha-adrenoreceptor agonists and antagonists in a maze exploration model of "fear"-motivated behavior. Naunyn Schmiedebergs Arch. Pharmacol. 327:1984;1-5.
16. Heilig M., McLeod S., Koob G.K., Britton K.T. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul. Pept. 41:1992;61-69.
17. Heilig M., Soderpalm B., Engel J.A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology. 98:1989;524-529.
18. 1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increased feeding. Regul. Pept. 59:1995;201-205.
19. Jacques D., Dumont Y., Fournier A., Quirion R. Characterization of neuropeptide Y receptor subtypes in the normal human brain, including the hypothalamus. Neuroscience. 79:1997;129-148.
20. Kask A., Harro J., von Horsten S., Redrobe J.P., Dumont Y., Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci. Biobehav. Rev. 26:2002;259-283.
21. 1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone (CRH)-induced anxiety. Neuroscience. 104:2001;799-806.
22. 1 receptor antagonist BIBP3226: antagonism with diazepam. Eur. J. Pharmacol. 317:1996;R3-R4.
23. 1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats. Regul. Pept. 75/76:1998;255-262.
24. 1 receptors in the dorsal periaqueductal gray matter regulate anxiety in the social interaction test. Neuroreport. 9:1998;2713-2716.
25. 13-36 microinjected into the vicinity of locus coeruleus in rats. Brain Res. 788:1998;345-348.
26. 2 receptor antagonist, BIIE0246 on neuropeptide Y release. Eur. J. Pharmacol. 396:2000;R1-R3.
27. Larhammar D. Evolution of neuropeptide Y. Regul. Pept. 62:1996;1-11.
28. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D.et al. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50:1998;143-150.
29. Montgomery K.C. The relation between fear induced by novel stimulation and exploratory behavior. J. Comp. Physiol. Psychol. 48:1958;254-260.
30. 2-type receptors. Peptides. 19:1998;359-363.
31. Parker R.M.C., Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur. J. Neurosci. 11:1999;1431-1448.
32. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
33. 3H ]5-HT release in raphe Neuroreport. 7:1995;353-359.
34. 2+ entry. J. Neurosci. 17:1997;8169-8177.
35. 1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology. 26:2002;615-624.
36. Redrobe J.P., Dumont Y., Quirion R. Neuropeptide Y as a potential target for the treatment of depressive illness: Y not? Neurosci. News. 4:2001;61-68.
37. Redrobe J.P., Dumont Y., Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci. 71:2002;2921-2937.
38. Redrobe J.P., Dumont Y., St-Pierre J.A., Quirion R. Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Res. 848:1999;153-166.
39. Rodgers R.J., Johnson N.J.T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52:1995;297-303.
40. 2 receptors in body weight regulation revealed in conditional knockout mice. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8938-8943.
41. 2 receptors mediate anxiety in the amygdala. Pharmacol. Biochem. Behav. 71:2002;419-423.
42. Sajdyk T.J., Vandergriff M.G., Gehlert D.R. Amygdalar neuropeptide Y Y-1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur. J. Pharmacol. 368:1999;143-147.
43. Smith-White M.A., Herzog H., Potter E.K. Role of neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission. Regul. Pept. 103:2002;105-111.
44. Stanley B.G., Leibowitz S.F. Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci. 35:1984;2635-2642.
45. Stogner K.A., Holmes P.V. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. J. Pharmacol. 387:2000;R9-R10.
46. 2 receptors in rat thalamic neurons. J. Physiol. 531:2001;81-94.
47. Trillat A.C., Malagie I., Scearce K., Pons D., Anmella M.C., Jacquot C.et al. Regulation of serotonin release in the frontal cortex and ventral hippocampus of homozygous mice lacking 5-HT1B receptors: in vivo microdialysis studies. J. Neurochem. 69:1997;2019-2025.
48. Vezzani A., Sperk G., Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 22:1999;25-30.
49. 2 receptor antagonist BIIE0246 on presynaptic inhibition by neuropeptide Y in hippocampal slices. Eur. J. Pharmacol. 404:2000;133-136.